Medical Policy


Subject: Powered Robotic Lower Body Exoskeleton Devices
Document #: OR-PR.00006 Publish Date:    12/27/2017
Status: Reviewed Last Review Date:    11/02/2017


This document addresses the use of powered, robotic lower body exoskeleton devices that may be utilized in the rehabilitation of or for daily use by individuals with neurological disorders that affect an individual’s ability to ambulate without assistance.

Note: For information regarding other prosthesis, please see the following:

Position Statement

Investigational and Not Medically Necessary:

The use of a powered, robotic lower body exoskeleton device is considered investigational and not medically necessary under all circumstances, including but not limited to the following:


In a pilot study, Zeilig et al. (2012) evaluated the safety and tolerance of the ReWalk (Argo Medical Technologies, Inc., Marlborough, MA) exoskeleton ambulation suit in a small case series of 6 subjects with complete motor spinal cord injury (SCI) between T5 and T12.  Subjects averaged 33.2 years of age, weighed less than 100 kg, and were 155 to 200 cm in height.  All subjects underwent several 50-minute-long training sessions to achieve ambulation with a powered robotic lower body exoskeleton device to walk a 100 meter (m) long path.  Following this acclimation, a battery of tests, including timed up and go (TUG), distance walked in 6 minutes, and a 10 m timed walk were performed.  No falls, skin or joint injuries, cardiovascular events or changes on spine radiographs were reported.  Several technical issues related to the device were reported; all were resolved.  Use of the system was generally well-tolerated, with no increase in pain and a moderate level of fatigue after use.  Three participants with lower lesions (T9-T12) walked longer distances than the three with higher lesions (T5-T7) (mean 66.3 m vs. mean 22.7 m; p<0.01).  In the 10 m walk test, participants with lower levels of injury walked faster than those with higher levels of injury (mean 47 seconds vs. mean 85.7 seconds; p<0.05).  Level of injury did not influence the results in the TUG test or the number of training sessions needed before subjects were ready for testing (p=0.15 and p=0.42 respectively).  In this small sample, age and time from injury did not influence any of the test measures.  Individuals with lower level of SCI performed walking more efficiently.  The authors concluded that volunteer participants were able to ambulate with the ReWalk for a distance of 100 m with no adverse effects during the course of an average of 13 to 14 training sessions.  The participants were generally positive regarding the use of the system.  The authors stated that the potential benefits of the ReWalk are many, including improved functional mobility, cardiovascular and respiratory status, bone metabolism, and bowel and bladder function, as well as reduction of spasticity and neuropathic pain, but such claims remain unsubstantiated by clinical trial data.  The researchers noted that this study did not include any female subjects, individuals with quadriplegia, children, or older adults. 

A small, noncomparative study of 12 paraplegic subjects with thoracic level (T3-T12) SCI evaluated the safety and ability of ReWalk to enable individuals with paraplegia due to SCI to carry out routine ambulatory functions (Esquenazi, 2012).  Following approximately 8 weeks of acclimation training involving 24 60- to 90-minute sessions, all subjects were successful in independently transferring and walking in the ReWalk for at least 50 to 100 meters continuously, for a period of at least 5 to 10 minutes with velocities ranging from 0.03 to 0.45 m/sec (mean of 0.25 m/sec).  Excluding 2 subjects with considerably reduced walking abilities, average distances and velocities improved significantly.  Most subjects achieved a level of walking proficiency close to that needed for limited community ambulation.  A high degree of performance variability was observed across individuals.  Some of this variability was explained by level of injury, but other factors have not been completely identified.  Some subjects reported improvements in pain, bowel and bladder function, and spasticity during the trial.  No falls, bone fractures, or episodes of autonomic dysreflexia occurred.  Of the 12 subjects, 5 had a definite or possible study-related mild to moderate adverse event, including skin abrasions, lightheadedness, and edema of the lower limbs.  The authors concluded that the ReWalk system holds considerable potential as a safe, ambulatory powered orthosis for individuals with motor-complete thoracic-level SCI. 

In 2013, Esquenazi et al. published a small, randomized comparative trial involving 16 subjects with traumatic brain injury (TBI).  This study compared the use of the ReWalk device in treadmill assisted rehabilitation training (n=8) vs. manually assisted treadmill rehabilitation training (n=8).  Following training, the average self-selected walking velocity (SSV) increased by 49.8% for the ReWalk group (p=0.01) and by 31% for the manual group (p=0.06).  The average maximal velocity increased by 14.9% for the ReWalk group (p=0.06) and by 30.8% for the manual group (p=0.01).  Step-length asymmetry ratio improved during SSV by 33.1% for the ReWalk group (p=0.01) and by 9.1% for the manual group (p=0.73).  The distance walked increased by 11.7% for the ReWalk group (p=0.21) and by 19.3% for manual group (p=0.03).  While each group demonstrated benefits from their assigned training method, no differences between groups were reported.  The value of the ReWalk system in rehabilitation training following TBI is unclear given these results. 

Spungen (2013) reported the results of a pilot study from the Bronx Veterans Affairs Hospital of a trial of the ReWalk system in 7 subjects with paraplegia due to SCI with permanent paralysis and loss of mobility.  The study was not published in a peer-reviewed medical journal, but was made available on a Veterans Affairs website.  This pre/post intervention pilot case series was performed to determine the number of sessions and level of assistance needed to execute standing, walking, and stair climbing skills with the ReWalk device.  Subjects were studied over an average of 45 ± 20 sessions consisting of 1 to 2 hours of standing and overground ambulation for 3 sessions per week.  All 7 participants learned to perform sit-to-stand, stand-to-sit, and ambulation to 50 to 166 meters in 6 minutes with no (n=4) to varying (n=3) levels of assistance.  Ascending and descending ≥ 5 stairs with assistance was achieved by 4 subjects.  These same 4 subjects also achieved some outdoor-specific walking skills.  The authors reported that there was no relationship with achievement of exoskeletal-assisted mobility skills and the duration or level of SCI.

A small comparative study of 6 subjects with motor-complete SCI and 3 able-bodied volunteers using the ReWalk devices was reported by Fineberg and others in 2013.  All subjects underwent 1-2 hours of combined sitting and walking sessions 3 times per week for 5 to 6 months.  The objective of the study was to use vertical ground reaction force (vGRF) to show the magnitude and pattern of mechanical loading in subjects during walking using the F-Scan™ in-shoe pressure mapping system.  The investigators measured the pressure imparted to both the left and right feet in all SCI subjects while walking in the ReWalk device and in control subjects during unassisted walking.  Three of the SCI subjects participated in the measurement trials using assistive devices such as walkers and the remaining 3 were unassisted.  For measurements of peak stance average (PSA) the assisted SCI group had significantly lower vGRF vs. control subjects (p<0.05).  No significant difference in PSA was noted between the no-assist SCI group and controls.  Significant differences between the assist and no assist SCI groups was also noted, with the no-assist group subjects creating greater VGRF than the assisted subjects (p=0.0095 for midstance and p=0.045 for toe off).  The authors concluded that powered exoskeleton-assisted walking in individuals with motor-complete SCI generated vGRF similar in magnitude and pattern to that of able-bodied walking.  They suggested these results demonstrated the potential for powered exoskeleton-assisted walking to provide a mechanism for mechanical loading to the lower extremities in individuals with SCI.

Asselin and others (2015) reported the results of a small case series study of 8 non-ambulatory subjects with paraplegia who were trained to ambulate with the ReWalk device.  The authors reported that the average value of oxygen update (VO2) during walking with the device was significantly higher in all subjects vs. when sitting and standing (p<0.001).  Also, the heart rate response during walking with the device was significantly greater vs. when subjects were either sitting or standing (p<0.001).  These findings are not unexpected, and align with what is commonly known about human physiology.  The authors concluded that individuals with paraplegia are able to ambulate efficiently using the powered exoskeleton for overground ambulation, providing potential for functional gain and improved fitness.  This study provided no data regarding the safety of the device.

Yang and colleagues (2015) described a cohort study involving 12 SCI subjects evaluated for assisted walking speed while using the ReWalk device and assistive Lofstrand crutches.  All subjects underwent 10-meter walking tests and 6-minute walking tests, with the shortest time for the 10-meter test and the furthest distance for the 6-minute test counted as the best effort.  Over a median of 55 training sessions, 7 of 12 subjects were able to ambulate at greater than or equal to 0.4 m/s.  The authors reported an inverse relationship was noted for level of assistance and walking velocity for both the 6-minute test (p<0.0086) and the 10-meter test (p=0.0088).  No serious adverse events were reported.  There were 13 episodes of mild skin abrasions reported, and all resolved with padding and equipment adjustments.

A case series study involving 16 subjects with SCI was conducted to evaluate mobility outcomes for individuals with SCI following five training sessions (Hartigan, 2015).  All subjects underwent five 90-minute training sessions with the Indego® exoskeleton device followed by the 10-meter walk test and the 6-minute walk test with the Indego devices in addition to an assistive device.  Additional outdoor tasks were also evaluated during the training sessions, including walking on sidewalks, up and down Americans with Disabilities Act (ADA) compliant ramps, and over grass.  Three subjects had motor complete quadraplegia (C5-C7 level injury), 5 had upper paraplegia (T1-T8 level injury), and 8 had lower paraplegia (T9-L1 level injury).  One half of the subjects were able to ambulate on both indoor and outdoor surfaces, elevators and ramps, and most used an assistive device and minimal or moderate assistance.  The average distance covered during a 6-minute walk time test was 64 meters for subjects with quadraplegia, 76 meters for those with upper paraplegia, and 121 meters for those with lower paraplegia.  Seven of the subjects were able to don and doff the system independently.

Stampacchia (2016) published the findings of a cohort study investigating the impact of the Ekso GT exoskeleton system on pain and spasticity.  They enrolled 21 subjects with partial or complete SCI due to traumatic or non-traumatic lesions.  All subjects underwent a single 40-minute session of sitting to standing to walking with the Ekso device in addition to an assistive walking device (rollator).  Prior to and after the session, subjects completed a subjective rating scale (1 to 10) measuring both pain and spasticity.  Spasticity was further measured with the Modified Ashworth scale (MAS) and the Penn Spasm Frequency Scale (PSFS).  Walking behavior was deemed to be homogenous throughout the sample based upon walking time and number of steps taken.  Following the walking session, perceived spasticity was improved significantly using a subjective rating scale (p<0.001), as well as on the MAS and PSFS scales (p<0.001 for both).  Overall, perceived pain was not significantly changed, but when looking at the subset of subjects with pain prior to the session, significant pain reductions were reported (p<0.002).  No correlation was noted between the reduction in pain and the reduction in spasticity. 

A second smaller cohort study published in 2016 evaluated the quality of life impact of the institutional version of the ReWalk device on 7 subjects with SCI (Platz, 2016).  All subjects underwent one 4 to 5-week intensive inpatient device-training session which included 60 minutes of exoskeleton training 5 days per week in addition to individualized therapeutic exercise regimens as indicated.  Training sessions included sit-to-stand, stand-to-sit, 2-arm standing balance, 1-arm standing balance, 10 meter walking straight ahead, 10 meter walking in a curve, climbing a set of 12 stairs, and 500 meter outdoor walk.  Evaluations included milestones for these activities and satisfaction with training and device use.  With the exception of the last two activities mentioned above, all subjects met the expected milestones.  Sit-to-stand and stand-to-sit were achieved by all subjects within two training sessions.  Indoor walking was achieved by all subjects within 2 weeks.  The majority of subjects were able to achieve these activities, as well as 1- and 2-arm standing balance activities without physical assistance or occasional help.  Only 4 subjects achieved climbing the 12 the steps.  No data were provided for the 500 meter walk evaluation.  The authors reported a “fair” degree of satisfaction with the training.  Pre/post measures of the physical domain of the SF-36v2 indicated significant improvements, but no other domain demonstrated significant changes.  No significant adverse events were reported, including falls and cardiovascular events.  Skin lesions were reported in 4 subjects, but were resolved with adjustment of the device and discontinuation of the training was not necessary.  Mild pain or swelling were reported in 4 subjects.  No changes in motor or sensory signs, spasticity or activities of daily living competence were reported.

A third small cohort study was published in 2016 by Benson and colleagues.  This trial involved 10 subjects with C7-T12 SCI trained to use the ReWalk device in twice weekly session for a total of 20 sessions.  Only 5 subjects completed the full trial; 2 decided not to continue with the training, 2 experienced recurrent skin breakdown requiring discontinuation, and a fifth experienced a fractured talus.  The mean number of weeks required to complete the 20 sessions for the 5 remaining subjects was 19 weeks.  The average number of sessions before a subject was deemed ready for stairs training was six.  Improvements in spasticity were noted in the 2 subjects with mild spasticity prior to training (Ashworth scale -0.70).  Over the course of training, all 5 subjects experienced improvements in gait speed, walking distance, speed to standing up, rotating, and sitting.  Stair ascent and descent was achieved by 4 subjects.  No significant benefits were noted in the 10-meter walk time test or the Timed Up and Go (TUG) test, however, some improvements were noted in the 6-minute walk test.  Measures on the Appraisals of Disability: Primary and Secondary Scale (ADAPASS) showed mixed results, with improvements seen in the primary scales, but not in any of the six subscales.  Results on the Assistive Technology Device Predisposition Assessment (ATD-PA) did not demonstrate significant improvements in functional abilities or personal characteristics.

A meta-analysis of the clinical effectiveness and safety of powered exoskeleton devices was published by Miller et al. in 2016.  The investigators included 11 studies involving 111 subjects using the ReWalk (8 studies), Ekso™ (3 studies), and Indego (2 studies) devices.  An additional study involved an unspecified device.  Considerable heterogeneity was present across studies with regard to training methods and duration, and outcomes, including ambulatory performance, metabolic demand, and perceived health benefits.  No serious adverse events were reported.  The incidence of falls during training was 4.4%, and all three falls were reported in the same study (Kozlowski, 2015).  These falls were attributed to programming errors in the first generation Ekso device in 2 cases and to a crutch malfunction in the third.  The authors concluded that, “Powered exoskeletons allow patients with SCI to safely ambulate in real-world settings at a physical activity intensity conducive to prolonged use and known to yield health benefits.”  However, this conclusion is weakened by the fact that the majority of studies took place in the investigational setting.

A small cohort study involving 5 subjects with traumatic C7-T10 SCI and minimal spasticity was published by Karelis and others in 2017.  All subjects underwent a 6-week long training period involving three 3 hour-long training sessions per week with the Ekso device.  No changes in the American Spinal Injury Association Impairment Scale (AIS) were reported following completion of the training sessions.  Significant changes were noted for leg and appendicular lean body mass, and total leg and appendicular fat mass.  Total BMI increased significantly.  No serious injuries were reported.

Kozlowski (2017) reported the findings of the first study involving the use of a powered exoskeleton device in 5 subjects with multiple sclerosis (MS).  This cohort study involved individuals with Expanded Disability Status Scale (EDSS) scores ranging from 5.5 to 7.0, medically stable, fit the ReWalk device, could tolerate standing for 30 minutes, and were > 1 year since relapse.  Evaluations were taken at baseline and at weeks 1, 4, 8 (baseline period), 12 and 16 (intervention period) and at week 20 (follow-up).  Subjects underwent three 30- to 90-minute training sessions per week for a total of 24 sessions.  The study originally enrolled 13 subjects, but 2 failed screening and 6 withdrew, either due to transportation issues or device-related pain.  A total of 5 subjects completed > 20 walking sessions.  The investigators commented that regression of progress was noted with gaps in the training interval that exceeded 4 days, but losses were usually regained within one session.  Learnability was considered high, with most participants attaining walking and sitting well within the 24 session limit.  No serious adverse events were reported, but skin issues were common, with 151 events per 1000 hrs of exposure to training.  Qualitative postural improvements were reported for 4 of the 5 subjects.  No overall improvement was reported with regard to the Neuro-QOL and Patient Reported Outcome Measurement and Information System (PROMIS) tools.

In 2017, Molteni published the results of the first study investigating the use of a powered exoskeleton device in subjects who had experienced a stroke.  This study involved 23 subjects who were trained to use the Ekso device in 12 1-hour long sessions over 4 weeks (3 sessions per week).  The authors stratified their findings by subject condition, with 12 sub-acute (< 180 days from acute event) and 11 chronic (> 180 days from acute event).  For the subacute subjects, the total scores on the motricity index (MI) revealed significant improvements at 6 and 12 weeks (p=0.0078 and p=0.001, respectively).  MI measures for hip and knee at 6 and 12 weeks also demonstrated significant benefits (p=0.0078 and p=0.002 for hip, p=0.0131 and p=0.0078 for knee, respectively).  Improvements in the MI ankle level were significant at 12 weeks.  The Trunk Control Test (TCT) showed significant changes at both 6 and 12 weeks (p=0.0078 and p=0.0039, respectively).  The Functional Ambulation Scale (FAC) had similar results (p=0.001 for both 6 and 12 weeks).  Ambulation was achieved in 2 nonambulatory subjects.  No significant improvements were noted in the 10-meter walk test or in the number of steps.  Finally, for this group, significant improvements were reported in walking velocity and the 6-minute walk test at both 6 and 12 weeks (p=0.0234 and p=0.0078 for velocity, respectively and p=0.0156 and p=0.0039 for 6-minute walk, respectively).  In the chronic group, no significant changes were found on the Ashworth scale, which measures lower limb spasticity.  With respect to MI scores, the total score did show significant improvements at 6 and 12 weeks (p=0.0156 and p=0.0078, respectively), but only at the hip level (p=0.0156 for both time points), but not at the knee or ankle levels.  No significant changes were reported for the TCT, 10-meter walk test, or steps taken.  Findings on the FAC were significantly improved at 12 weeks (p=0.0313), walking velocity improved significantly as well at both time points (p=0.0155 for both), as did the results of the 6-minute walking test (p=0.0156 and p=0313, respectively).

On June 26, 2014, the U.S. Food and Drug Administration (FDA) approved the ReWalk robotic lower body exoskeleton device with the following approved indications:

…is intended to enable individuals with spinal cord injury at levels T7-L5 to perform ambulatory functions with supervision of a specifically trained companion in accordance with the user assessment and training certification program. The device is also intended to enable individuals with spinal cord injury at levels T4-T6 to perform ambulatory functions in rehabilitation institutions in accordance with the user assessment and training certification program. The ReWalk™ is not intended for sports or stair climbing.

At this time, the available published evidence addressing the safety and efficacy of robotic lower body exoskeleton devices is limited to small studies.  There is insufficient evidence of durable effectiveness, tolerability and safety.


Robotic lower body exoskeleton devices are intended to allow individuals with loss of lower limb function to ambulate on their own.  When used, the device is worn outside clothing and consists of an upper-body harness, lower-limb braces, motorized joints, ground-force sensors, a tilt sensor, a locomotion-mode selector, and a backpack carrying a computerized controller and rechargeable battery.  Using a wireless remote control worn on the wrist, the user commands the device to stand up, sit down, or walk.  The device is strapped to the user at the waist, alongside each lower limb, and at the feet.  Ordinary crutches are also utilized to help maintain stability. 

There are currently several FDA approved robotic lower body exoskeleton devices on the market, including the ReWalk exoskeleton, the Ekso and Ekso GT, and the Indego.  The FDA-approved indications for these devices include use by individuals with hemi- and paraplegia due to spinal cord injuries or stroke when accompanied by a specially trained caregiver.  They may also be used in rehabilitation institutions.  None of these types of devices are intended for sports or climbing stairs.  For some of these devices, candidates must retain upper-limb strength and mobility to manage stabilizing crutches. 


The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services are Investigational and Not Medically Necessary:





Lower extremity orthoses, not otherwise specified [when specified as a powered robotic lower body exoskeleton device]





ICD-10 Diagnosis



All diagnoses



Peer Reviewed Publications:

  1. Asselin PK, Avedissian M, Knezevic S, et al. Training persons with spinal cord injury to ambulate using a powered exoskeleton. J Vis Exp. 2016; (112).
  2. Asselin P, Knezevic S, Kornfeld S, et al. Heart rate and oxygen demand of powered exoskeleton-assisted walking in persons with paraplegia. J Rehabil Res Dev. 2015; 52(2):147-158.
  3. Benson I, Hart K, Tussler D, van Middendorp JJ.  Lower-limb exoskeletons for individuals with chronic spinal cord injury: findings from a feasibility study. Clin Rehabil. 2016; 30(1):73-84.
  4. Esquenazi A, Lee S, Packel AT, Braitman L. A randomized comparative study of manually assisted versus robotic-assisted body weight supported treadmill training in persons with a traumatic brain injury. PM R. 2013; 5(4):280-290.
  5. Esquenazi A, Talaty M, Packel A, Saulino M. The ReWalk powered exoskeleton to restore ambulatory function to individuals with thoracic-level motor-complete spinal cord injury. Am J Phys Med Rehabil. 2012; 91(11):911-921.
  6. Evans N, Hartigan C, Kandilakis, Acute cardiorespiratory and metabolic responses during exoskeleton-assisted walking overground among persons with chronic spinal cord injury. Top Spinal Cord Inj Rehab. 2015; 21(2):122-132.
  7. Fineberg DB, Asselin P, Harel NY, et al. Vertical ground reaction force-based analysis of powered exoskeleton-assisted walking in persons with motor-complete paraplegia. J Spinal Cord Med. 2013; 36(4):313-321.
  8. Hartigan C, Kandilakis C, Dalley S, et al. Mobility outcomes following five training sessions with a powered exoskeleton. Top Spinal Cord Inj Rehabil. 2015; 21(2):93-99.
  9. Karelis AD, Carvalho LP, Castillo MJ, et al. Effect on body composition and bone mineral density of walking with a robotic exoskeleton in adults with chronic spinal cord injury. J Rehabil Med. 2017; 49(1):84-87.
  10. Kozlowski AJ, Bryce TN, Dijkers MP. Time and effort required by persons with spinal cord injury to learn to use a powered exoskeleton for assisted walking. Top Spinal Cord Inj Rehabil. 2015; 21(2):110-121.
  11. Kozlowski AJ, Fabian M, Lad D, Delgado AD. Feasibility and safety of a powered exoskeleton for assisted walking for persons with multiple sclerosis: a single-group preliminary study. Arch Phys Med Rehabil. 2017; 98(7):1300-1307.
  12. Lonini L, Shawen M, Scanlon K, Accelerometry-enabled measurement of walking performance with a robotic exoskeleton: a pilot study. J Neuroeng Rehab. 2016; 13(35):142-149.
  13. Miller LE, Zimmermann AK, Herbert WG. Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis. Med Devices (Auckl). 2016; 9:455-466.
  14. Molteni F, Gasperini G, Gaffuri M, et al. Wearable robotic exoskeleton for over-ground gait training in sub-acute and chronic hemiparetic stroke patients: preliminary results. Eur J Phys Rehabil Med. 2017 Jan 24. [Epub ahead of print]
  15. Platz T, Gillner A, Borgwaldt N, et al. Device-training for individuals with thoracic and lumbar spinal cord injury using a powered exoskeleton for technically assisted mobility: achievements and user satisfaction. Biomed Res Int. 2016; 2016:8459018.
  16. Stampacchia G, Rustici A, Bigazzi S, et al. Walking with a powered robotic exoskeleton: subjective experience, spasticity and pain in spinal cord injured persons. NeuroRehabilitation. 2016; 39(2):277-283.
  17. Talaty M, Esquenazi A, Briceno JE. Differentiating ability in users of the ReWalk(TM) powered exoskeleton: an analysis of walking kinematics. IEEE Int Conf Rehabil Robot. 2013; 2013:6650469.
  18. Yang A, Asselin P, Knezevic S, et al. Assessment of in-hospital walking velocity and level of assistance in a powered exoskeleton in persons with spinal cord injury. Top Spinal Cord Inj Rehabil. 2015; 21(2):100-109.
  19. Zeilig G, Weingarden H, Zwecker M, et al. Safety and tolerance of the ReWalk™ exoskeleton suit for ambulation by people with complete spinal cord injury: a pilot study. J Spinal Cord Med. 2012; 35(2):96-101.

Government Agency, Medical Society, and Other Authoritative Publications:

  1. Spungen AM, Asselin P, Fineberg DB, et al.; VA Rehabilitation Research and Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury. Exoskeletal-assisted walking for persons with motor-complete paraplegia. Research and Technology Organization, Human Factors, and Medicine Panel: North Atlantic Treaty Organization; 2013.

Ekso GT

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Document History






Medical Policy & Technology Assessment Committee (MPTAC) review. The document header wording updated from “Current Effective Date” to “Publish Date.” Updated Rationale and References sections.



MPTAC review. Updated References section.



MPTAC review. Updated Rationale and Reference sections. Removed ICD-9 codes from Coding section.



MPTAC review. Initial document development.